Jill S Gordon, AUD | |
4257 Us Highway 9 Bldg 6, Freehold Office Plaza, Freehold, NJ 07728-8310 | |
(732) 303-9660 | |
(732) 303-1810 |
Full Name | Jill S Gordon |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 4257 Us Highway 9 Bldg 6, Freehold, New Jersey |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023195484 | NPI | - | NPPES |
7939809 | Medicaid | NJ |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | YA00174 (New Jersey) | Primary |
237600000X | Audiologist-hearing Aid Fitter | MG00564 (New Jersey) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jill S Gordon, AUD 4257 Us Highway 9 Bldg 6, Freehold Office Plaza, Freehold, NJ 07728-8310 Ph: (732) 303-9660 | Jill S Gordon, AUD 4257 Us Highway 9 Bldg 6, Freehold Office Plaza, Freehold, NJ 07728-8310 Ph: (732) 303-9660 |
News Archive
Western Dental Services, Inc., California's neighborhood dentist and one of the nation's leading dental health maintenance organizations, is opening a family dentistry, specialty and orthodontics office in Gilroy, on July 30 - during the city's famous Garlic Festival.
EKF Molecular Diagnostics has agreed a collaboration with specialist medtech company ANGLE plc, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan™ DNA enrichment technology as a liquid biopsy. If successful, the resulting simple blood test could enable the investigation of unexpected ultra-low level mutations in a patient's cancer for personalised cancer care.
Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).
Plextronics, Inc. announced today that it has completed a $14 million Series B-1 financing round. The round was led by Solvay North American Investments, LLC, a member of the Solvay Group, which is an international chemical and pharmaceutical group headquartered in Brussels, Belgium. Marking Solvay's second investment in three years, this $12 million investment makes Solvay the largest minority shareholder in Plextronics.
Staff who work with dementia patients should receive education about the condition as a mandatory component of both employment criteria and staff development programs, say Australian researchers.
› Verified 1 days ago